[Monitoring of treatment involving 5-fluorocytosine].
The occurrence of hematologic and neurologic complications probably caused by an overdose of 5-FC has prompted us to study 5-FC pharmacokinetics in 10 patients under a 5-FC and amphotericin B. On the basis of our findings we have determined the optimal dosage that achieves desired concentrations. In 5 cases this dosages was found to differ from that suggested by the manufacturer. 5-FC concentrations were however higher than predicted levels as a result of the association with amphotericin B. A subsequent modification of dosage was needed in 10 patients. 5 undesirable side effects were recorded: thrombopenia (1 case), neutropenia (1 case), diarrhea (2 cases), and isolated rise in transaminases. In 4 patients with high 5-FC concentrations, chromatograms showed a peak possibly formed by 5-FU, suggesting that 5-FC may be converted into 5-FU.
D000666:Amphotericin B / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy; D003596:Cytosine / Q000031:analogs & derivatives*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005437:Flucytosine / Q000009:adverse effects / Q000097:blood* / Q000627:therapeutic use; D005472:Fluorouracil / Q000097:blood; D006801:Humans; D007700:Kinetics
D000666:Amphotericin B; D003596:Cytosine; D005437:Flucytosine; D005472:Fluorouracil
Contribution à la surveillance des traitements comportant de la 5-fluorocytosine.